Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Le Mans – page 19

289 clinical trials in Le Mans, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Le Mans at a glance
289
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

289 trials in Le Mans

Open in trial search

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Breast cancer

Not recruiting

Study of Imlunestrant, Fulvestrant, Exemestane, and Abemaciclib for Patients with Advanced Estrogen Receptor Positive, HER2 Negative Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Anti-neutrophil cytoplasmic antibody positive vasculitis+1

Not recruiting

Study on Continuing or Stopping Immunosuppressive Therapy with Rituximab in Patients with ANCA Vasculitis and End-stage Kidney Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Centre Hospitalier Departemental Vendee

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Metastatic squamous cell carcinoma

Not recruiting

Study on Chemotherapy with Cisplatin, Fluorouracil, and Docetaxel for Patients with Locally Advanced Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Diffuse large B-cell lymphoma

Not recruiting

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

B-cell lymphoma+1

Not recruiting

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer stage IV+1

Not recruiting

Study of Relatlimab and Nivolumab with Chemotherapy for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan with or without Pertuzumab for Patients with HER2-positive Metastatic Breast Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Axial spondyloarthritis

Not recruiting

Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Le Mans

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on multiple myeloma treatments, including evaluations of new combination therapies and maintenance approaches. Studies also explore treatments for head and neck cancers and advanced prostate cancer.

  • Multiple Myeloma Treatment Optimization
  • Prostate Cancer Therapeutics
  • Head and Neck Cancer Innovation

Several trials are investigating novel immunotherapy combinations and targeted treatments to improve patient outcomes.

02 Respiratory Medicine

Critical research in lung cancer and pleural mesothelioma, with studies evaluating immunotherapy combinations and novel treatment approaches for previously treated patients.

  • Non-Small Cell Lung Cancer Therapy
  • Mesothelioma Treatment Innovation
  • Immunotherapy Combinations

Focus on developing personalized treatment strategies for advanced respiratory cancers.

03 Immunology Studies

Comprehensive research into systemic lupus erythematosus and plaque psoriasis, evaluating new biological treatments and long-term therapeutic solutions.

  • Autoimmune Disease Management
  • Psoriasis Treatment Development
  • Immunotherapy Safety Profiles

Trials aim to improve treatment outcomes while maintaining patient safety and quality of life.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.